771580-86-0

Usage

Uses

Used in Pharmaceutical Industry:
DBM is utilized as a reagent in chemical reactions for the synthesis of pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its ability to introduce the dibromophenylmethyl group into other molecules makes it a valuable component in the creation of diverse pharmaceutical compounds.
Used in Agricultural Industry:
In the agricultural sector, DBM is employed as a precursor in the production of agrochemicals, such as pesticides and herbicides. Its chemical properties allow for the development of effective and targeted agricultural products that can enhance crop protection and yield.
Used in Dye Industry:
DBM also finds application in the dye industry, where it is used as a building block for the synthesis of various dyes and pigments. Its unique chemical structure enables the creation of dyes with specific properties, such as color intensity and stability, for use in textiles, plastics, and other materials.
Used as a Precursor in Chemical Synthesis:
DBM is used as a precursor in the production of various organic molecules, including pharmaceuticals and agrochemicals. Its versatility in chemical reactions allows for the synthesis of a wide range of compounds with diverse applications.
It is crucial to handle DBM with care due to its potential hazards to human health and the environment. Proper safety measures and disposal methods should be followed to minimize any adverse effects.

Upstream product

• 97165-77-0 3,5-dibromobenzonitrile 

Downstream Products

• 911425-14-4 (1RS)-N-(3,5-dibromobenzyl)-1-[4-(tert-butyloxycarbonyl)-1-piperazinyl]-1-indancarboxamide 

Relevant academic research and scientific papers

FACTOR XI ACTIVATION INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.

ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS

Provided are compounds of the Formula I, and salts and solvates thereof: (I) wherein R1, R2, R3, R6, X1, X2 and Z are defined in the specification. The compounds are inhibitors of salt-inducible kinase (SIK), particular SIK2, and are useful in therapy, particularly in the treatment of a proliferative disorder, a benign neoplasm, pathological angiogenesis, an inflammatory disease or condition, a musculoskeletal disease or condition, an autoimmune disease, a haematological disease or condition, a neurological disease or condition, a psychiatric disorder, or a metabolic disorder.

ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS

Provided are compounds of the Formula I, and salts and solvates thereof: (I) wherein R1, R2, R3, X1, X2, X3 and Z are defined in the specification. The compounds are inhibitors of salt-inducible kinase (SIK), particular SIK2, and are useful in therapy, particularly in the treatment of a proliferative disorder, a benign neoplasm, pathological angiogenesis, an inflammatory disease or condition, a musculoskeletal disease or condition, an autoimmune disease, a haematological disease or condition, a neurological disease or condition, a psychiatric disorder, or a metabolic disorder.

Aminoacetamide acyl guanidines as beta-secretase inhibitors

There is provided a series of substituted acyl guanidines of Formula (Ik) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R2, R3, R4, R5, R25, R26 and R27 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.